Optimi Health is trading 5.3% down at $4.12, pressured by broad market weakness after hotter-than-expected producer inflation lifted yields and reduced rate-cut optimism.
- The stock followed a 10.12% decline on September 9.
- Major U.S. indices are down more than 0.5%.
- On September 10, Optimi Health announced a Health Canada-authorized Phase 2 psilocybin trial for major depressive disorder, which does not explain the same-direction decline. [Event ID: 6aa2b94d098edf0569c721c8]